Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Invenomic Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustainable, AI-driven valuation bubble."
For September 2025, the Invenomic Fund returned -5.63%, underperforming the S&P 1500 Index (+3.42%) due to a historic momentum surge that detracted roughly 4.5% from the fund's short book. Despite the underperformance, Invenomic outlines deep concerns about the current market environment. They highlight that the Shiller CAPE has crossed 40x (approaching the dotcom bubble peak of 44x) and that the Russell 1000 Growth's outperformance of Value is at an all-time 33-month high. The manager believes the AI bubble is showing signs of fundamental decay, as heavy capital expenditures yield low incremental returns, revenue remains anemic, and aggressive late-90s style accounting is emerging. Consequently, the fund is positioned defensively, maintaining a 19.8% average net exposure (112.6% long, -92.8% short).
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Growth Outlook
Market outlook remains low conviction: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Risk Appetite
Risk appetite posture is low conviction: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Forward Guidance
Forward guidance signal: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Language Signal
Tone analysis indicates high conviction language: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Perceived Risk
Perceived risk level is evaluated as high conviction. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Opportunity Density
Opportunity density index indicates low conviction actionable entry points. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Time Horizon
Investment time horizon reflects a above average conviction orientation. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
